This was a large collaboration between labs at UC Davis, China Medical University, University of Kansas, Washington University in St Louis, and Karyopharm Therapeutics. This study characterized a new small molecule inhibitor of PAK4 that specifically kills cystic renal epithelial cells, and is now being evaluated in a clinical trial.
The manuscript was published in Kidney International and can be found here.